Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration

Critical Care Medicine

Volumn 46, Issue 1, 2018, Pages 21-28

  Meyer, Nuala J ^a   Reilly, John P ^a   Anderson, Brian J ^a   Palakshappa, Jessica A ^a   Jones, Tiffanie K ^a   Dunn, Thomas G ^a   Shashaty, Michael G S ^a   Feng, Rui ^b   Christie, Jason D ^a,b   Opal, Steven M ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

heterogeneous treatment effect; interleukin 1 receptor antagonist; predictive enrichment; sepsis

Indexed keywords

ANAKINRA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; IL1R1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR TYPE I; RECOMBINANT PROTEIN;

ADULT; APACHE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PERFUSION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEPSIS; SURVIVAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; INTENSIVE CARE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

APACHE; CRITICAL CARE; FEMALE; HUMANS; INTERLEUKIN-1BETA; KAPLAN-MEIER ESTIMATE; MALE; RECEPTORS, INTERLEUKIN-1 TYPE I; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85038230942     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002749     Document Type: Article

References (54)

1. Fleischmann C Scherag A Adhikari NK; International Forum of Acute Care Trialists: Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016; 193: 259 272
2. Singer M Deutschman CS Seymour CW. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801 810
3. Opal SM Dellinger RP Vincent JL. The next generation of sepsis clinical trial designs: What is next after the demise of recombinant human activated protein C? Crit Care Med 2014; 42: 1714 1721
4. Freidlin B Korn EL. Biomarker enrichment strategies: Matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014; 11: 81 90
5. Mehta C Schäfer H Daniel H. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Stat Med 2014; 33: 4515 4531
6. Flaherty KT Robert C Hersey P; METRIC Study Group: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107 114
7. Shaw AT Yeap BY Solomon BJ. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011; 12: 1004 1012
8. Kellum JA Pike F Yealy DM; and the Protocol-based Care for Early Septic Shock Investigators (ProCESS) Investigators: Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: Analysis of the protocol-based care for early septic shock study. Crit Care Med 2017; 45: 438 445
9. Granowitz EV Porat R Mier JW. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353 360
10. Granowitz EV Clark BD Mancilla J. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147 14150
11. Herold S Tabar TS Janssen H. Exudate macrophages attenuate lung injury by the release of IL-1 receptor antagonist in gram-negative pneumonia. Am J Respir Crit Care Med 2011; 183: 1380 1390
12. Ganter MT Roux J Miyazawa B. Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circ Res 2008; 102: 804 812
13. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095 2147
14. Okusawa S Gelfand JA Ikejima T. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162 1172
15. Dinarello CA Ikejima T Warner SJ. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902 1910
16. Leff JA Bodman ME Cho OJ. Post-insult treatment with interleukin-1 receptor antagonist decreases oxidative lung injury in rats given intratracheal interleukin-1. Am J Respir Crit Care Med 1994; 150: 109 112
17. Wang F Meyer NJ Walley KR. Causal genetic inference using haplotypes as instrumental variables. Genet Epidemiol 2016; 40: 35 44
18. Meyer NJ Ferguson JF Feng R. A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med 2014; 190: 656 664
19. Fisher CJ Jr Slotman GJ Opal SM; IL-1RA Sepsis Syndrome Study Group: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12 21
20. Fisher CJ Jr Dhainaut JF Opal SM. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836 1843
21. Opal SM Fisher CJ Jr Dhainaut JF. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115 1124
22. Bone RC Balk RA Cerra FB. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864 874
23. Rubenfeld GD Angus DC Pinsky MR. Outcomes research in critical care. Am J Respir Crit Care Med 1999; 160: 358 367
24. Knaus WA Harrell FE Fisher CJ Jr. The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA 1993; 270: 1233 1241
25. Knaus WA Wagner DP Draper EA. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619 1636
26. Kent DM Rothwell PM Ioannidis JP. Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. Trials 2010; 11: 85
27. Wang R Lagakos SW Ware JH. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189 2194
28. Brookes ST Whitely E Egger M. Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004; 57: 229 236
29. Fluss R Faraggi D Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47: 458 472
30. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32 35
31. Mantel N Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719 748
32. Graubard BI Korn EL. Predictive margins with survey data. Biometrics 1999; 55: 652 659
33. Shakoory B Carcillo JA Chatham WW. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. Crit Care Med 2016; 44: 275 281
34. Kaukonen KM Bailey M Pilcher D. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015; 372: 1629 1638
35. Kellum JA Kong L Fink MP; GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655 1663
36. Casey LC Balk RA Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771 778
37. Wakabayashi G Gelfand JA Burke JF. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338 343
38. Ohlsson K Björk P Bergenfeldt M. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550 552
39. Marshall SW. Power for tests of interaction: Effect of raising the type I error rate. Epidemiol Perspect Innov 2007; 4: 4
40. Rossi-Semerano L Fautrel B Wendling D; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation): Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis 2015; 10: 19
41. Boomer JS To K Chang KC. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594 2605
42. Monneret G Lepape A Voirin N. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006; 32: 1175 1183
43. Pachot A Monneret G Voirin N. Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin Immunol 2005; 114: 61 69
44. Tschaikowsky K Hedwig-Geissing M Schiele A. Coincidence of pro-and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002; 30: 1015 1023
45. van Vught LA Klein Klouwenberg PC Spitoni C. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016; 315: 1469 1479
46. Chang K Svabek C Vazquez-Guillamet C. Targeting the programmed cell death 1: Programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014; 18: R3
47. Goldie AS Fearon KC Ross JA. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274: 172 177
48. Dinarello CA Cannon JG. Cytokine measurements in septic shock. Ann Intern Med 1993; 119: 853 854
49. Granowitz EV Clark BD Vannier E. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992; 79: 2356 2363
50. Crasto CL Semba RD Sun K. Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults. J Gerontol A Biol Sci Med Sci 2011; 66: 437 443
51. Thavasu PW Longhurst S Joel SP. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 1992; 153: 115 124
52. Ranieri VM Suter PM Tortorella C. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA 1999; 282: 54 61
53. Meyer NJ Feng R Li M. IL1RN coding variant is associated with lower risk of acute respiratory distress syndrome and increased plasma IL-1 receptor antagonist. Am J Respir Crit Care Med 2013; 187: 950 959
54. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 2005; 365